No Data
China Securities Co., Ltd.: Q2 albumin batch issuance is the same as last year, and hepatitis B batch issuance has resumed growth.
The blood product industry is expected to maintain steady growth in the first half of 24H1. In the second half of the year, the industry is expected to continue the tight supply and demand pattern. The leading companies in the industry are expected to achieve continuous increase in plasma collection and profitability, and have more competitive advantages.
ChinareS Pharma (03320.HK) has entered into a property leasing and property management services agreement with Chinare Holdings.
On July 23, Gelunhui announced that on July 23, 2024, the company and Chinares Group signed a property leasing and property management services framework agreement. According to this, Chinares Group will provide leasing properties and/or multiple property management services to the Group, with a period from July 23, 2024 to December 31, 2025.
Chongqing Gas Group's Profit Drops 11% in H1
Market Chatter: Korea's GC Group to Sell Hong Kong Unit to CR Pharmaceutical
CICC: Maintains 'outperform' rating on ChiaRes Pharma (03320), with a target price of HKD 7.3.
CICC predicts chinares pharma's EPS to be 0.69 yuan in 2024 and 0.77 yuan in 2025.
China Resources Pharmaceutical Unit to Purchase Holding Company of Blood Product Firm
No Data
